Telomir receives Nasdaq non-compliance notice for missing annual meeting; has until Feb 23 to submit plan

Telomir Pharmaceuticals, Inc.

Received Nasdaq notice on Jan 8, 2026 for failure to hold annual meeting within 12 months of fiscal year end (Rule 5620(a)).
No immediate delisting; trading continues. Must submit compliance plan by Feb 23, 2026.
Preliminary proxy filed Nov 20, 2025 still under SEC review; expects to hold meeting promptly after clearance.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.